Patent opinions from the Eastern District of Texas and the U.S. Court of Appeals for the Federal Circuit

Weekly Digest
Fed. Cir.

Endo Pharmaceuticals Inc. v. Mylan Pharmaceuticals, No. 14-1324 (Fed. Cir. May 30, 2014)

Granted in Part
Court
U.S. Court of Appeals for the Federal Circuit
Case No.
No. 14-1324
Decided
May 30, 2014
Judge
Newman, J.
Document
Order on Motion
Length
3 pages

NOTE: This order is nonprecedential. United States Court of Appeals

for the Federal Circuit

ENDO PHARMACEUTICALS INC.,

Plaintiff-Cross-Appellant,

v.

MYLAN PHARMACEUTICALS INC. AND MYLAN

INC.,

Defendants-Appellants.

2014-1324, -1365

Appeals from the United States District Court for the District of Delaware in No. 1:11-cv-00717-RMB-KW, Judge Renee Marie Bumb.

ENDO PHARMACEUTICALS INC.,

Plaintiff-Appellant,

v.

MYLAN PHARMACEUTICALS INC. AND MYLAN

INC.,

Defendants-Appellees.

2014-1422

2Appeal from the United States District Court for the District of Delaware in No. 1:11-cv-00717-RMB-KW, Judge Renee Marie Bumb.

ON MOTION

Before NEWMAN, Circuit Judge.

O R D E R

Mylan Pharmaceuticals Inc. and Mylan Inc. (Mylan) move without opposition to reactivate and dismiss Appeal Nos. 2014-1324, -1365. Mylan also moves to dismiss certain portions of Endo Pharmaceuticals Inc.’s Appeal No. 2014-1422. Endo opposes dismissal of Appeal No. 2014-1422.

These appeals all stem from the same district court action. In Appeal No. 2014-1422, Endo appeals from the district court’s grant of Mylan’s Rule 60(b) motion, which vacated the judgment previously challenged in Appeal Nos. 2014-1324, -1365, as well as other orders. Mylan’s motion seeks to limit Endo’s appeal to the district court’s Rule 60(b) decision.

No briefs have yet been filed in this appeal. We deem it the better course for Mylan to raise any issues concerning jurisdiction in its brief.

Accordingly,

IT IS ORDERED THAT:

(1) Mylan’s motion to reactivate and dismiss Appeal Nos. 2014-1324, -1365 is granted.

3(2) Each party shall bear its own costs in Appeal Nos. 2014-1324, -1365. (3) Mylan’s motion to dismiss Appeal No. 2014-1422 is denied.

(4) The opening brief in 2014-1422 shall be due no later than June 20, 2014. FOR THE COURT

/s/ Daniel E. O’Toole

Daniel E. O’Toole

Clerk of Court

ISSUED AS A MANDATE (As To 14-1324, -1365 Only): May 30, 2014

s30

Text extracted from the official PDF and reflowed for reading. It is not a certified transcript — the PDF linked above is the authoritative document.

Analysis is coming soon.

A plain-English account of the issues, facts and holding, written by Patent Case Watch. The opinion itself — its full text, its PDF and everything else on this page — stays free to read for everyone, always.

Cite this opinion

Endo Pharmaceuticals Inc. v. Mylan Pharmaceuticals, No. 14-1324 (Fed. Cir. May 30, 2014).

Record ID
CAFC-14-1324-20140530
Permalink
https://patentcasewatch.com/opinions/CAFC-14-1324-20140530

No reporter citation is shown because the official source does not supply one; none is inferred here. Check the opinion and a citator before relying on this form.